CAR T Cell Therapy News

News Image

The California Institute for Regenerative Medicine today awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop CAR T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells.

City of Hope Joins Parker Institute | City of Hope

City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.


Saul Priceman | City of Hope

Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.


Linda Malkas Town and Country

City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.


Leo David Wang Bio Photo

The complex process of cell division is being studied at City of Hope by a team of stem cell biologists led by Leo David Wang, M.D., Ph.D.


City of Hope Joins Parker Institute | City of Hope

City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.


News Image

FDA approves tisagenlecleucel (commercial name Kymriah) CAR T cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Cheryl Wiers CAR T | City of Hope

Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.


Chuck Fata was involved in a CAR T cell trial at City of Hope.

CAR T Cells Save Chuck Fata's Life


Saul Priceman | City of Hope

City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.


News Image

City of Hope today announced that it is a certified treatment center to administer tisagenlecleucel (commercial name Kymriah) chimeric antigen receptor (CAR) T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration (FDA) – to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

CAR T

City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.


News Image

City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.

CAR T Trio Researchers | City of Hope

Often unrecognized are the countless folks who work in the spaces between the lab and the clinic — people responsible for doing everything from manufacturing CAR T cells to gaining federal approval for new trials.